TNFRSF1A and metabolic dysfunction-associated steatotic liver disease: In this regard, transgenic NAFLD mice lacking TNF-α receptors (tnfr−/−) were protected from severe hepatic steatosis [22, 23], whereas treatment of NAFLD mice with anti-TNF antibody or selective anti-TNFR1 antibody attenuated hepatic steatosis [24, 25].